Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04172987 · ClinicalTrials.gov registry record · Phase 1
A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT04172987 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 40 participants.
The verdict
NCT04172987, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to look at how the body processes the commonly prescribed birth control pill, ethinylestradiol + norgestimate (EE/NGM), in healthy female participants and the effect of tirzepatide on how EE/NGM is processed by the body. Information about any side effects that may occur will also be collected. Screening is required within 28 days prior to the start of the study. For each participant, the study will last about 20 weeks, including screening.
Interventions
- DRUG Tirzepatide
- DRUG EE/NGM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2020-02-26 |
| Est. Completion | 2021-02-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04172987
The ClinicalTrials.gov registry entry for NCT04172987 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tirzepatide is the first listed.
NCT04172987 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04172987 about?
NCT04172987 is a clinical study titled "A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants". The purpose of this study is to look at how the body processes the commonly prescribed birth control pill, ethinylestradiol + norgestimate (EE/NGM), in healthy female participants and the effect of tirzepatide on how EE/NGM is processed by the body. Information about any side effects that may occur ...
What is the current status of trial NCT04172987?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2020-02-26. Estimated completion is 2021-02-09.
What interventions are being tested in trial NCT04172987?
The interventions under investigation include: Tirzepatide (DRUG), EE/NGM (DRUG).
Who is sponsoring clinical trial NCT04172987?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.